Carlo Contreras, MD, discusses areas of planned and ongoing research with neoadjuvant therapies in basal cell carcinoma and cutaneous squamous cell carcinoma.
Bobbie J. Rimel, MD, discusses the importance of testing patients with ovarian cancer for homologous recombination deficiency (HRD) or homologous recombination proficiency (HRP), and BRCA mutation status.
Chan Cheah, MBBS, discusses the investigation of BGB-11417 with or without zanubrutinib in chronic lymphocytic leukemia.
Charu Aggarwal, MD, MPH, discusses treating patients with EGFR-mutant non–small cell lung cancer.
Daniel J. George, MD, discusses the clinical benefits of evaluating phenotype in metastatic castration-resistant prostate cancer.
Suchita Pakkala, MD, discusses ongoing efforts to integrate local therapy into HER2-positive breast cancer treatment.
Jorge M. Mercado, MD, discusses the effect of the COVID-19 pandemic on lung cancer screening.
Sandra P. Susanibar-Adaniya, MD, discusses important considerations when treating patients with multiple myeloma.
Daniel J. George, MD, discusses the importance of understanding mutations in prostate cancer.
Heather Jim, PhD, discusses a real-world analysis, examining the quality of life outcomes seen with axicabtagene ciloleucel in patients with relapsed/refractory large B-cell lymphoma.
Amit Singal, MD, discusses the FDA approval of durvalumab with tremelimumab (Imjudo) in unresectable hepatocellular carcinoma.
Ran Reshef, MD, discusses findings from the phase 3 BMT CTN 1703 trial examining graft-vs-host disease prophylaxis in reduced intensity conditioning.
Regis Peffault de Latour, MD, PhD, discusses the benefit observed with iptacopan vs standard-of-care eculizumab or ravulizumab in patients with paroxysmal nocturnal hemoglobinuria and residual anemia during the phase 3 APPLY-PNH trial.
Max S. Topp, MD, discusses the efficacy of the combination of glofitamab plus R-CHOP from a phase 1 trial done in previously untreated patients with diffuse large B-cell lymphoma.
Alexander I. Spira, MD, PhD, FACP, discusses the FDA approval of adagrasib in patients with KRAS G12C–mutated non–small cell lung cancer.
Jeremy Abramson, MD, discusses the efficacy data of second-line lisocabtagene maraleucel vs standard-of-care salvage chemotherapy followed by autologous stem cell transplant from the phase 3 TRANSFORM trial done in patients with relapsed/refractory large B-cell lymphoma.
Ajay Chari, MD, discusses findings from the phase 1/2 MonumenTAL-1 trial investigating talquetamab in heavily pretreated patients with relapsed/refractory multiple myeloma.
Jesus G. Berdeja, MD, discusses the investigation of BMS-986393 in patients with relapsed/refractory multiple myeloma.
Mafalda Oliveira, MD, PhD, discusses the examination of camizestrant vs fulvestrant in estrogen receptor-positive, HER2-negative advanced breast cancer.
Manish Patel, DO, discusses updates in treatment with a PD1 and CTLA-4 inhibitor in non–small cell lung cancer.
Claire F. Verschraegen, MD, discusses the need to improve the management of treatment-related adverse effects of immunotherapy in melanoma.
Daniel J. George, MD, discusses the use of niraparib for patients with metastatic castration-resistant prostate cancer harboring BRCA and ATM mutations.
Joshua K. Sabari, MD, discusses the importance of timely testing for uncommon mutations in non–small cell lung cancer.
Nicholas C. Rohs, MD, discusses databases of uncommon mutations in non–small cell lung cancer
Akash Mukherjee, MD, discusses the implications of the FDA approval of lisocabtagene maraleucel in large B-cell lymphoma.
John Moroney, MD, discusses the evaluation of COM701 plus BMS-986207 and nivolumab in platinum-resistant ovarian cancer.
Oladapo Yeku, MD, PhD, FACP, discusses the evaluation of COM701 with nivolumab in patients with platinum-resistant epithelial ovarian cancer.
William Jacot, MD, PhD, discusses updated efficacy and safety results from the phase 2 AMALEE trial.
Sara A. Hurvitz, MD, discusses sequencing therapeutic options for patients with HER2-positive breast cancer.
Jason Romancik, MD, discusses efforts to maximize the efficacy of CAR T-cell therapy in non-Hodgkin lymphoma.
